Relapse acute lymphoblastic leukemia (ALL) is associated with chemotherapy resistance and poor prognosis. Persistent leukemia initiating cells with increased self-renewal capacity, clonal heterogeneity and selection of resistance-driving genetic alterations have been proposed as drivers of leukemia relapse. Gain of function mutations in the 5'-Nucleotidase, Cytosolic II (NT5C2) gene are selectively present in relapsed ALL and confer resistance to chemotherapy with 6-mercaptopurine (6-MP). Yet, the specific mechanisms mediating constitutive activation of NT5C2 and the role of these mutations as drivers of clonal evolution during leukemia initiation and disease progression remain unknown. Here we used a combination of structure function and crystallographic analyses to uncovered new intra-molecular mechanisms of NT5C2 regulation specifically targeted by relapsed leukemia-associated mutations. In addition, using an in vivo leukemia model we have explored the role and mechanisms of NT5C2 mutations in clonal evolution during tumor initiation, disease progression and relapse. These results have important implications for monitoring of leukemia relapse driving clones and for the development of targeted therapies for the treatment of relapsed disease.

Adolfo Ferrando M.D., Ph.D.
Associate Professor of Pediatrics and Pathology
Institute for Cancer Genetics
Columbia University

Host: Dr. John Dick  
Date: Thursday July 20th, 2017  
Time: 2PM  
Place: Donnelly Centre, 160 College St Red Seminar Room